Cargando…

Levetiracetam-induced leukocytoclastic vasculitis

Drug-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity-dependent areas. Vasculitis occurs within weeks after initial administration of medication and demonstrates clearance upon withdrawal of medication. Levetirace...

Descripción completa

Detalles Bibliográficos
Autor principal: Gupta, Mrinal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351226/
https://www.ncbi.nlm.nih.gov/pubmed/28458437
http://dx.doi.org/10.4103/0253-7613.201020
_version_ 1782514736053616640
author Gupta, Mrinal
author_facet Gupta, Mrinal
author_sort Gupta, Mrinal
collection PubMed
description Drug-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity-dependent areas. Vasculitis occurs within weeks after initial administration of medication and demonstrates clearance upon withdrawal of medication. Levetiracetam, a pyrrolidone derivative, is used as an adjunctive therapy in patients with refractory focal epilepsy, myoclonic epilepsy, and primary generalized tonic–clonic seizures. We present a case of a 14-year-old female, who developed cutaneous small-vessel vasculitis within 8 days of initiation of levetiracetam. Vasculitis was successfully managed by discontinuation of medication and systemic corticosteroids. This adverse reaction, to the best of our knowledge, has not been previously reported in literature.
format Online
Article
Text
id pubmed-5351226
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53512262017-04-28 Levetiracetam-induced leukocytoclastic vasculitis Gupta, Mrinal Indian J Pharmacol Drug Watch Drug-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity-dependent areas. Vasculitis occurs within weeks after initial administration of medication and demonstrates clearance upon withdrawal of medication. Levetiracetam, a pyrrolidone derivative, is used as an adjunctive therapy in patients with refractory focal epilepsy, myoclonic epilepsy, and primary generalized tonic–clonic seizures. We present a case of a 14-year-old female, who developed cutaneous small-vessel vasculitis within 8 days of initiation of levetiracetam. Vasculitis was successfully managed by discontinuation of medication and systemic corticosteroids. This adverse reaction, to the best of our knowledge, has not been previously reported in literature. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5351226/ /pubmed/28458437 http://dx.doi.org/10.4103/0253-7613.201020 Text en Copyright: © 2017 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Drug Watch
Gupta, Mrinal
Levetiracetam-induced leukocytoclastic vasculitis
title Levetiracetam-induced leukocytoclastic vasculitis
title_full Levetiracetam-induced leukocytoclastic vasculitis
title_fullStr Levetiracetam-induced leukocytoclastic vasculitis
title_full_unstemmed Levetiracetam-induced leukocytoclastic vasculitis
title_short Levetiracetam-induced leukocytoclastic vasculitis
title_sort levetiracetam-induced leukocytoclastic vasculitis
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351226/
https://www.ncbi.nlm.nih.gov/pubmed/28458437
http://dx.doi.org/10.4103/0253-7613.201020
work_keys_str_mv AT guptamrinal levetiracetaminducedleukocytoclasticvasculitis